Biogen Inc. (NASDAQ: BIIB) Stock Competitors & Peer Comparison
See BIIB's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BIIB and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIIB | $215.50 | -1.62% | 31.8B | 13.60 | $15.84 | N/A |
| LLY | $1,152.22 | -0.02% | 1.1T | 36.61 | $31.49 | +0.58% |
| JNJ | $269.99 | -0.09% | 650.6B | 25.16 | $10.73 | +1.94% |
| ABBV | $263.78 | -0.09% | 466.1B | 25.89 | $10.19 | +2.58% |
| MRK | $146.76 | -0.27% | 362.5B | 45.72 | $3.21 | +2.32% |
| NVS | $140.37 | -0.39% | 266.8B | 16.15 | $8.69 | +3.38% |
| AZN | $166.08 | -0.04% | 257.5B | 17.93 | $9.26 | +1.94% |
| AMGN | $385.65 | +2.47% | 205B | 16.98 | $22.37 | +2.58% |
| NVO | $43.24 | +0.12% | 192B | 10.76 | $4.02 | +4.13% |
| GILD | $150.11 | -0.52% | 186.4B | -384.90 | -$0.39 | +2.15% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
BIIB vs LLY Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while LLY trades at $1,152.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas LLY's P/E ratio is 36.61. In terms of profitability, BIIB's ROE is +0.05%, compared to LLY's ROE of +0.93%. Regarding short-term risk, BIIB is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
BIIB vs JNJ Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, JNJ has a market cap of 650.6B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while JNJ trades at $269.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas JNJ's P/E ratio is 25.16. In terms of profitability, BIIB's ROE is +0.05%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, BIIB is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
BIIB vs ABBV Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, ABBV has a market cap of 466.1B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while ABBV trades at $263.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas ABBV's P/E ratio is 25.89. In terms of profitability, BIIB's ROE is +0.05%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, BIIB is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
BIIB vs MRK Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, MRK has a market cap of 362.5B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while MRK trades at $146.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas MRK's P/E ratio is 45.72. In terms of profitability, BIIB's ROE is +0.05%, compared to MRK's ROE of +0.07%. Regarding short-term risk, BIIB is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check MRK's competition here
Novartis AG (NYSE: NVS)
BIIB vs NVS Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, NVS has a market cap of 266.8B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while NVS trades at $140.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas NVS's P/E ratio is 16.15. In terms of profitability, BIIB's ROE is +0.05%, compared to NVS's ROE of +0.30%. Regarding short-term risk, BIIB is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
BIIB vs AZN Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, AZN has a market cap of 257.5B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while AZN trades at $166.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas AZN's P/E ratio is 17.93. In terms of profitability, BIIB's ROE is +0.05%, compared to AZN's ROE of +0.22%. Regarding short-term risk, BIIB is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
BIIB vs AMGN Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, AMGN has a market cap of 205B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while AMGN trades at $385.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas AMGN's P/E ratio is 16.98. In terms of profitability, BIIB's ROE is +0.05%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, BIIB is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
BIIB vs NVO Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, NVO has a market cap of 192B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while NVO trades at $43.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas NVO's P/E ratio is 10.76. In terms of profitability, BIIB's ROE is +0.05%, compared to NVO's ROE of +0.59%. Regarding short-term risk, BIIB is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
BIIB vs GILD Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, GILD has a market cap of 186.4B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while GILD trades at $150.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas GILD's P/E ratio is -384.90. In terms of profitability, BIIB's ROE is +0.05%, compared to GILD's ROE of -0.16%. Regarding short-term risk, BIIB is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
BIIB vs PFE Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, PFE has a market cap of 157.3B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while PFE trades at $27.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas PFE's P/E ratio is 9.05. In terms of profitability, BIIB's ROE is +0.05%, compared to PFE's ROE of +0.05%. Regarding short-term risk, BIIB is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
BIIB vs BMY Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, BMY has a market cap of 128.8B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while BMY trades at $63.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas BMY's P/E ratio is 10.63. In terms of profitability, BIIB's ROE is +0.05%, compared to BMY's ROE of +0.47%. Regarding short-term risk, BIIB is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check BMY's competition here
Sanofi (NASDAQ: SNY)
BIIB vs SNY Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, SNY has a market cap of 102B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while SNY trades at $42.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas SNY's P/E ratio is 9.25. In terms of profitability, BIIB's ROE is +0.05%, compared to SNY's ROE of +0.06%. Regarding short-term risk, BIIB is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check SNY's competition here
GSK plc (NYSE: GSK)
BIIB vs GSK Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, GSK has a market cap of 100.6B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while GSK trades at $50.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas GSK's P/E ratio is 10.85. In terms of profitability, BIIB's ROE is +0.05%, compared to GSK's ROE of +0.24%. Regarding short-term risk, BIIB is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check GSK's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
BIIB vs HZNP Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas HZNP's P/E ratio is 61.86. In terms of profitability, BIIB's ROE is +0.05%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, BIIB is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
BIIB vs GRFS Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, GRFS has a market cap of 6.2B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while GRFS trades at $7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas GRFS's P/E ratio is 8.40. In terms of profitability, BIIB's ROE is +0.05%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, BIIB is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
BIIB vs OGN Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while OGN trades at $13.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas OGN's P/E ratio is 4.09. In terms of profitability, BIIB's ROE is +0.05%, compared to OGN's ROE of +0.23%. Regarding short-term risk, BIIB is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
BIIB vs AMRN Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, AMRN has a market cap of 286.9M. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while AMRN trades at $13.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas AMRN's P/E ratio is -138.70. In terms of profitability, BIIB's ROE is +0.05%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, BIIB is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check AMRN's competition here
Scilex Holding Company (NASDAQ: SCLX)
BIIB vs SCLX Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, SCLX has a market cap of 42.8M. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while SCLX trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas SCLX's P/E ratio is -0.13. In terms of profitability, BIIB's ROE is +0.05%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, BIIB is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check SCLX's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
BIIB vs MIRA Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, MIRA has a market cap of 34.2M. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while MIRA trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas MIRA's P/E ratio is -0.56. In terms of profitability, BIIB's ROE is +0.05%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, BIIB is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLXW)
BIIB vs SCLXW Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, SCLXW has a market cap of 33.6M. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while SCLXW trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas SCLXW's P/E ratio is N/A. In terms of profitability, BIIB's ROE is +0.05%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, BIIB is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
BIIB vs BDSIW Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, BIIB's ROE is +0.05%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, BIIB is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
BIIB vs CRXT Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 31.8B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, BIIB is priced at $215.50 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 13.60, whereas CRXT's P/E ratio is -0.02. In terms of profitability, BIIB's ROE is +0.05%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, BIIB is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check CRXT's competition here